Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162403 · ClinicalTrials.gov registry record · NA
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
A NA study of Chemotherapy-induced Peripheral Neuropathy and Peripheral Nerve Stimulation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06162403: Recruiting NA study of Chemotherapy-induced Peripheral Neuropathy and Peripheral Nerve Stimulation, sponsored by M.D. Anderson Cancer Center.
NCT06162403 is a NA study of Chemotherapy-induced Peripheral Neuropathy and Peripheral Nerve Stimulation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06162403, a NA study of Chemotherapy-induced Peripheral Neuropathy and Peripheral Nerve Stimulation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- OTHER Peripheral Nerve Stimulation
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06162403 shows while recruiting
NCT06162403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Peripheral Nerve Stimulation is the first listed.
NCT06162403 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06162403 about?
NCT06162403 is a clinical study titled "Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study". To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.
What is the current status of trial NCT06162403?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-02-22. Estimated completion is 2027-12-31.
What conditions does trial NCT06162403 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy, Peripheral Nerve Stimulation.
What interventions are being tested in trial NCT06162403?
The interventions under investigation include: Peripheral Nerve Stimulation (OTHER).
Who is sponsoring clinical trial NCT06162403?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06162403 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06162403's enrollment target sits among peer trials
10 29th of 29 higher than 1 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression for CIPN
RECRUITING · NA
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI